Overview

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Status:
RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment

Phase:

PHASE4

Details

Lead Sponsor:

Centre Francois Baclesse

Treatments:

cabozantinib
Nivolumab